Alaska

1. **AK S 32**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

   **Title:** Biological Products  
   **Summary:** Relates to biological products; relates to the practice of pharmacy; relates to the Board of Pharmacy.

   **NORD:** NORD supports. Actions: Submitted written testimony and constituent messages  
   **Disposition:** Pending - Carryover  
   **Introduced:** 01/23/2017  
   **Author:** Hughes (R)  
   **Status:** 04/14/2017 From HOUSE Committee on HEALTH AND SOCIAL SERVICES: Do pass. (4-0)  
               04/14/2017 To HOUSE Committee on FINANCE.

Alabama

2. **AL HJR 115**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

   **Title:** Rare Disease Advisory Council  
   **Summary:** Establishes the Alabama rare disease advisory council.

   **NORD:** NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Arkansas

3. **AR H 1204**

**Title:** Biological Product Substitutions by Pharmacists

**Summary:** Allows pharmacists to make biological product substitutions; relates to pharmacy records, electronically accessible pharmacy records and pharmacy benefit management systems; requires a label showing the trade name or the proper name of the biological product.

**NORD:** NORD Supports

**Disposition:** Failed - Adjourned

**Introduced:** 01/18/2017

**Author:** Magie (D)

**Status:** 03/23/2017 WITHDRAWN by Author.

---

4. **AR H 1900**

**Title:** Health Insurance Coverage

**Summary:** Amends the requirements for health insurance coverage for medically necessary foods used in the treatment of inborn errors of metabolism; defines medical disorder requiring specialized nutrients or formulas; exempts benefits provided under the state Medicaid Program and certain limited benefit health insurance policies from these requirements.

**Disposition:** Enacted

**Introduced:** 03/03/2017

**Author:** Bentley (R)

**Status:** 04/07/2017 Signed by GOVERNOR. 04/07/2017 Act No. 1096

---

Arizona
5. **AZ S 1368**

- **Title:** Newborn Screening and Fees
- **Summary:** Relates to newborn screening; relates to fees.
- **NORD:** NORD Supports
- **Disposition:** Enacted
- **Introduced:** 01/26/2017
- **Author:** Allen (R)
- **Status:** 05/22/2017 Chapter No. 339

6. **CA A 1353**

- **Title:** Health Care Coverage: Prescription Drugs: Continuity
- **Summary:** Requires a health care service plan and health insurer that provides coverage for outpatient prescription drugs to establish an expeditious process by which enrollees and insureds or prescribing providers may obtain an exception to any prior authorization process or any other utilization management or medical management practices. Requires coverage for certain medically necessary nonformulary drugs.
- **NORD:** NORD Supports
- **Disposition:** Pending
- **Introduced:** 02/17/2017
- **Author:** Waldron (R)
- **Status:** 03/23/2017 From ASSEMBLY Committee on HEALTH with author's amendments. 03/23/2017 In ASSEMBLY. Read second time and amended. Re-referred to Committee on HEALTH.

7. **CA ACR 14**

- **Title:** Rare Disease Day
Colorado

8. CA S 643

Title: Duchenne Muscular Dystrophy
Summary: Adds Duchenne muscular dystrophy to the list of medical conditions eligible for the Holden-Moscone-Garamendi Genetically Handicapped Persons Program.

NORD: NORD Supports. Actions: Submitted written testimony to health committee and participating in coalition in support of the bill.

Disposition: Pending
Introduced: 02/17/2017
Author: Pan (D)
Status: 06/27/2017 From ASSEMBLY Committee on HEALTH: Do pass to Committee on APPROPRIATIONS. (15-0)

9. CO S 203

Title: Alternative Drug Requirement
Summary: Concerns the prohibition against a carrier requiring a covered person to undergo step therapy, and, in connection therewith, requiring coverage for a prescribed medication that is part of the carrier’s medication formulary.


Disposition: Enacted
Introduced: 02/28/2017
Sponsor: Todd (D)
Status: 06/07/2017 Session Law Chaptered. Chapter No. 296
10. **CT H 6009**

**Title:** Rare Disease Advisory Council  
**Summary:** Establishes a rare disease advisory council; makes recommendations on legislation concerning the rare disease community.

**NORD:** NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.

**Disposition:** Failed  
**Introduced:** 01/19/2017  
**Introducer:** Rose (D)  
**Status:** 03/29/2017 Failed Joint Favorable deadline.

11. **CT H 6622**

**Title:** Changes to Health Insurer Prescription Drug Formularies  
**Summary:** Limits changes to health insurers' prescription drug formularies; limits when health insurance policies may change prescription drug formularies during a policy term.

**NORD:** NORD Supports  
**Disposition:** Failed  
**Introduced:** 01/24/2017  
**Introducer:** Cook (D)  
**Status:** 03/16/2017 Failed Joint Favorable deadline.

12. **CT H 7118**

**Title:** Biological Products  
**Summary:** Concerns biological products; adds biological products to existing law regarding substitution of generic drugs.
13. **CT S 22**

- **Introduced:** 01/09/2017
- **Introducer:** Looney (D)
- **Status:** 03/16/2017 Failed Joint Favorable deadline.

**Title:** Cost Sharing for Prescription Drugs

**Summary:** Concerns cost-sharing for prescription drugs; assists citizens with prescription drug costs; imposes a coinsurance, copayment, deductible or other out-of-pocket expense that exceeds a specified sum for a covered prescription drug.

**NORD:** NORD Supports this legislation.

**Disposition:** Failed

---

14. **CT S 545**

- **Introduced:** 01/23/2017
- **Introducer:** Kennedy (D)
- **Status:** 03/16/2017 Failed Joint Favorable deadline.

**Title:** Step Therapy Drug Regimens for Cancer Patients

**Summary:** Concerns a study of requests by health care providers to override step therapy drug regimens for certain cancer patients; requires a study and report on the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer.

**Disposition:** Failed

---
**Delaware**

**15. DE HCR 13**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Adopted</th>
</tr>
</thead>
</table>

**Title:** Rare Disease Day Resolution  
**Summary:** Recognizes March 22, 2017, as "Rare Disease Day" in Delaware.  
**Disposition:** Adopted  
**Introduced:** 03/22/2017  
**Primary Sponsor:** Baumbach (D)  
**Status:** 03/22/2017 INTRODUCED.  
03/22/2017 Passed HOUSE. *****To SENATE.  
03/22/2017 Passed SENATE. (19-0)

**Florida**

**16. FL H 95**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

**Title:** Nonmedical Changes To Prescription Drug Formularies  
**Summary:** Relates to consumer protection from nonmedical changes to prescription drug formularies; limits changes to prescription drug formularies during health insurance policy or HMO contract year; provides applicability; exempts state group insurance program; requires small employer carriers to limit changes to prescription drug formularies under certain circumstances; changes to a health maintenance contract prescription drug formulary during a contracted year.  
**NORD:** NORD supports this legislation.  
**Disposition:** Failed  
**Introduced:** 03/07/2017  
**Author:** Massullo (R)  
**Status:** 05/08/2017 In HOUSE. Died in committee.

**17. FL H 787**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>
Title: Health Insurance Coverage for Enteral Formulas
Summary: Relates to health insurance coverage for enteral formulas.
NORD: NORD supports this legislation.
Disposition: Failed
Introduced: 03/07/2017
Author: Slosberg E (D)
Status: 05/08/2017 In HOUSE. Died in committee.

Title: Newborn Screenings
Summary: Relates to newborn screenings; requires the Department of Health, upon the advice of the Genetics and Newborn Screening Advisory Council, to expand within a specified period the statewide screening of newborns to include any condition on the federal Recommended Uniform Screening Panel, contingent upon the availability of certain approved screening tests and an appropriation.
Disposition: Failed
Introduced: 03/07/2017
Author: Fitzenhagen (R)
Status: 04/27/2017 In HOUSE. Substituted on HOUSE floor by SB 1124
04/27/2017 In HOUSE. Laid on table, refer to SB 1124

Title: Prescription Drug Formularies
Summary: Relates to consumer protection from nonmedical changes to prescription drug formularies; limits changes to a health insurance policy prescription drug formulary during a policy year; requires small employer carriers to provide continuity of care for certain patients with respect to prescription drug coverage; limits changes to a health maintenance contract prescription drug formulary during a contract year.
NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Failed
Introduced: 03/07/2017
Author: Mayfield D (R)
20. **FL S 1124**

**Title:** Newborn Screenings

**Summary:** Relates to newborn screenings; requires the Department of Health, upon the advice of the Genetics and Newborn Screening Advisory Council, to expand within a specified period the statewide screening of newborns to include any condition on the federal Recommended Uniform Screening Panel; requires the council to determine whether a condition should be included in the state's screening program; requires the department to submit a legislative budget request to fund additional testing.

**NORD:** NORD supports this legislation. Actions: Submitted written testimony.

**Disposition:** Enacted

**Introduced:** 03/07/2017

**Author:** Book (D)

**Status:** 06/09/2017 Signed by GOVERNOR.
06/12/2017 Filed as Chapter No. 2017-78

---

21. **GA H 241**

**Title:** Krabbe Disease

**Summary:** Relates to control of hazardous conditions; adds Krabbe disease to the list of metabolic and genetic conditions for which newborn screening may be conducted pursuant to the Department of Public Health; provides for the screening at the option of the parent or parents; provides for payment of fees directly to the laboratory; relates to a system for prevention of serious illness, severe physical or developmental disability, and death resulting from inherited metabolic and genetic disorders.

**NORD:** NORD supports this legislation

**Disposition:** Enacted

**Introduced:** 02/02/2017

**Author:** Hawkins (R)

**Status:** 05/08/2017 Signed by GOVERNOR.
05/08/2017 Act No. 190
Title: Health Benefit Insurance Provisions
Summary: Relates to insurance generally, so as to require health benefit plans to utilize certain clinical review criteria to establish step therapy protocols; provides for a step therapy override determination process; provides for definitions; provides for statutory construction; provides for rules and regulations; provides for applicability; provides for related matters; repeals conflicting laws.

Disposition: Pending - Carryover
Introduced: 02/28/2017
Author: Cooper (R)
Status: 03/03/2017 In HOUSE: Read 2nd time.

Title: Health Insurance
Summary: Establishes requirements for step therapy protocols to ensure patient access to the particular prescription drugs prescribed by health care providers; establishes insurance coverage requirements and standards for appeal of coverage determinations.

Disposition: Pending - Carryover
Introduced: 01/24/2017
Author: Belatti (D)
Status: 03/09/2017 Failed First Crossover Deadline - First Year of Biennium.

Title: Prospective Review
Summary: Specifies procedural, disclosure, notice, and other requirements for prospective reviews required by health carriers or utilization review organizations prior to certification of coverage for health care services.
25. HI S 727

**Title:** Rare Disease Advisory Board

**Summary:** Establishes the rare disease advisory board within the Department of Health to provide education about rare diseases and encourage the funding of research in the development of new treatments for rare diseases; describes duties of the advisory board, members of the board, and the board's obligation to coordinate with local and national groups conducting similar research and advocacy for persons with rare diseases.

**Disposition:** Pending - Carryover

**Introduced:** 01/20/2017

**Author:** Green (D)

**Status:** 03/09/2017 Failed First Crossover Deadline - First Year of Biennium.

26. HI SCR 37

**Title:** Rare Disease Task Force

**Summary:** Urges the establishment of a rare disease task force.

**Disposition:** Failed - Adjourned

**Introduced:** 01/24/2017

**Author:** Green (D)

**Status:** 04/06/2017 Failed First Crossover Deadline - First Year of Biennium.
28. **IA H 233**

**Title:** Step Therapy Protocols  
**Summary:** Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations.  
**Disposition:** Enacted  
**Introduced:** 02/06/2017  
**Author:** House Human Resources Committee  
**Status:** 05/10/2017 Signed by GOVERNOR.

29. **IA H 305**

**Title:** Prescribing of Biological Products  
**Summary:** Relates to the prescribing of biological products; makes penalties applicable.  
**Disposition:** Enacted  
**Introduced:** 02/14/2017  
**Author:** House Human Resources Committee  
**Status:** 03/10/2017 Signed by GOVERNOR.

30. **IA HSB 26**
Title: Step Therapy Protocols for Prescription Drugs  
Summary: Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; includes applicability provisions.

NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Pending - Carryover
Introduced: 01/23/2017
Author: House Human Resources Committee
Status: 02/06/2017 In HOUSE. Becomes HOUSE File 233.

31. IA HSB 38  
Introduced | Passed 1st Committee | Passed 1st Chamber | Passed 2nd Committee | Passed 2nd Chamber | Enacted
--- | --- | --- | --- | --- | ---

Title: Prescribing of Biological Products  
Summary: Relates to the prescribing of biological products; makes penalties applicable.
Disposition: Pending - Carryover
Introduced: 01/24/2017
Author: House Human Resources Committee
Status: 02/14/2017 In HOUSE. Becomes HOUSE File 305.

32. IA S 51  
Introduced | Passed 1st Committee | Passed 1st Chamber | Passed 2nd Committee | Passed 2nd Chamber | Enacted
--- | --- | --- | --- | --- | ---

Title: Testing of Newborns  
Summary: Relates to a cytomegalovirus public health initiative and the testing of newborns for congenital cytomegalovirus; requires the center for congenital and inherited disorders to collaborate with state and local health agencies and other public and private organizations to develop and publish or approve and publish informational materials to educate and raise awareness of cytomegalovirus and congenital cytomegalovirus among women who may become pregnant, expectant parents, parents of infants.

NORD: NORD supports this legislation
Disposition: Enacted
Introduced: 01/11/2017
Author: Zaun (R)
Status: 04/20/2017 Signed by GOVERNOR.
33. **IA S 326**

**Title:** Prescribing of Biological Products

**Summary:** Relates to the prescribing of biological products; makes penalties applicable.

**Disposition:** Failed

**Introduced:** 02/22/2017

**Author:** Senate Human Resources Committee

**Status:** 03/01/2017 Withdrawn from further consideration.

---

34. **IA S 436**

**Title:** Step Therapy Protocols for Prescription Drugs

**Summary:** Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; includes applicability provisions.

**Disposition:** Failed

**Introduced:** 03/03/2017

**Author:** Senate Human Resources Committee

**Status:**
- 04/10/2017 In SENATE. Filed Amendment No. S-3301.
- 04/10/2017 In SENATE. Adopted Amendment No. S-3301.
- 04/10/2017 In SENATE. HOUSE File 233 substituted.
- 04/10/2017 Withdrawn from further consideration.

---

35. **IA SSB 1029**

**Title:** Biological Products

**Summary:** Relates to the prescribing of biological products; makes penalties applicable.

**Disposition:** Pending - Carryover

**Introduced:** 01/27/2017
36. **IA SSB 1072**

**Title:** Step Therapy Protocols  
**Summary:** Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; including applicability provisions.  
**Disposition:** Pending - Carryover  
**Introduced:** 02/08/2017  
**Author:** Senate Human Resources Committee  
**Status:** 02/21/2017 In SENATE Committee on HUMAN RESOURCES: Passed subcommittee.

---

37. **IL H 311**

**Title:** Network Adequacy and Transparency  
**Summary:** Creates the Network Adequacy and Transparency Act; provides that administrators and insurers, prior to going to market, must file for review and approval a description of services to be offered through a network plan, with certain criteria included in the description; provides that the network plan shall demonstrate a minimum ratio of full-time equivalent providers to plan beneficiaries and maximum travel and distance standards; relates to telemedicine, telehealth, or mobile care services.  
**NORD:** NORD supports this legislation. Actions: Submitted written testimony  
**Disposition:** To Governor  
**Introduced:** 01/11/2017  
**Sponsor:** Harris G (D)  
**Status:** 06/24/2017 HOUSE concurred in Senate Amendment No. 1. (98-0) 06/24/2017 Passed Both Houses.
**Title:** Managed Care Reform and Patient Rights  
**Summary:** Amends the Managed Care Reform and Patient Rights Act; in provisions concerning transition of services, provides that the health care plan shall not modify an enrollee's coverage of a drug during the plan year if the drug has been previously approved for coverage by the plan for a medical condition, the plan's prescribing provider continues to prescribe the drug for the medical condition, and the patient continues to be an enrollee of the health care plan.  
**Disposition:** Pending  
**Introduced:** 02/08/2017  
**Sponsor:** Harris G (D)  
**Status:** 03/31/2017 Rereferred to HOUSE Committee on RULES.

---

**Title:** Network Adequacy and Transparency  
**Summary:** Creates the Network Adequacy and Transparency Act; provides that administrators and insurers, prior to going to market, must file with the Department of Insurance for review and approval a description of the services to be offered through a network plan, with certain criteria included in the description; provides that the network plan shall demonstrate to the Department, prior to approval, a minimum ratio of full-time equivalent providers to plan beneficiaries and maximum travel and distance standards.  
**Disposition:** Pending  
**Introduced:** 01/11/2017  
**Sponsor:** Holmes (D)  
**Status:** 05/05/2017 Rule 3-9(a) / Re-referred to ASSIGNMENTS Committee.

---

**Title:** Electronic Authorization for Prescription Drugs  
**Summary:** Relates to electronic authorization for prescription drugs; requires certain health plans to accept and respond to electronic prior authorization requests according to a particular electronic transaction standard.  
**NORD:** NORD Supports this legislation.
Kansas

41. **KS H 2107**

- **Introduced:** 01/19/2017
- **Author:** House Health and Human Services Committee
- **Status:** 03/08/2017 Senate Hearing: Thursday, March 16, 2017, 09:30 AM Room 118-N.

**Title:** Biological Product Inclusion and the Pharmacy Act

**Summary:** Relates to inclusion of biological products in the pharmacy act of the state of Kansas.

**NORD:** NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.

**Disposition:** Pending - Carryover

42. **KS H 2151**

- **Introduced:** 01/25/2017
- **Author:** House Health and Human Services Committee
- **Status:** 01/26/2017 To HOUSE Committee on HEALTH AND HUMAN SERVICES.

**Title:** Health Insurance Use of Step Therapy Protocols

**Summary:** Establishes restrictions on health insurance use of step therapy protocols.

**Disposition:** Pending - Carryover

43. **KS S 82**
Title: Health Insurance Restrictions on Step Therapy Protocols
Summary: Establishes restrictions on health insurance use of step therapy protocols.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending - Carryover
Introduced: 01/25/2017
Author: Senate Public Health and Welfare Committee
Status: 02/08/2017 Senate Hearing: Monday, February 13, 2017, 09:30 AM Room 118-N.

---

DOCKET 1498
Title: Transparency and Access in Healthcare
Summary: Relates to transparency and access in healthcare.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/23/2017
Author: Benson (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

---

DOCKET 1503
Title: Management of Medications
Summary: Relates to management of medications.

Disposition: Pending
Introduced: 02/23/2017
Author: Benson (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.
46. MA H 1171

Introduced  Passes  Passes  Passes  Passes  Enacted
01/23/2017 1st Committee 1st Chamber 2nd Committee 2nd Chamber

DOCKET 1591
Title: Rare Disease Advisory Council
Summary: Establishes a rare disease advisory council.
Disposition: Pending
Introduced: 01/23/2017
Author: Heroux (D)
Status: 06/27/2017 In JOINT Committee on PUBLIC HEALTH: Heard. Eligible for Executive Session.

47. MA H 1650

Introduced  Passes  Passes  Passes  Passes  Enacted
02/24/2017 1st Committee 1st Chamber 2nd Committee 2nd Chamber

DOCKET 330
Title: Rare Disease Day Proclamation
Summary: Relates to the annual issuance of a proclamation by the Governor designating the last day of February as Rare Disease Day.
Disposition: Pending
Introduced: 02/24/2017
Author: Ashe (D)
Status: 02/27/2017 Filed as House Docket 330
02/27/2017 To JOINT Committee on STATE ADMINISTRATION AND REGULATORY OVERSIGHT. Dated 1/23/2017.

48. MA HD 390

Introduced  Passes  Passes  Passes  Passes  Enacted

DOCKET 1167
Title: Krabbe Disease in Newborn Screening
Summary: Includes Krabbe Disease in newborn screening.
NORD: NORD supports this legislation
49. MA HD 1591

**Title:** Rare Disease Advisory Council

**Summary:** Creates a Massachusetts Rare Disease Advisory Council.

**Disposition:** Pending

**Author:** Heroux (D)

**Status:** 02/24/2017 Assigned House Bill No. 1171

---

50. MA HD 3712

**Title:** Rare Disease Advisory Council

**Summary:** Creates a Massachusetts Rare Disease Advisory Council.

**Disposition:** Pending

**Author:** Heroux (D)

**Status:** 05/23/2017 Assigned House Bill No. 3714

---

51. MA S 516

**Title:** Prescription Drug Coverage

**Summary:** Relates to out-of-pocket expenses for prescription drug coverage.
Disposition: Pending
Introduced: 02/22/2017
Author: DiDomenico (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

**MA S 542**

**Introduced**  
**Passed 1st Committee**  
**Passed 1st Chamber**  
**Passed 2nd Committee**  
**Passed 2nd Chamber**  
**Enacted**

**DOCKET** 1029  
**Title:** Prescription Drug Coverage Out of Pocket Expenses  
**Summary:** Makes out-of-pocket expenses for prescription drug coverage more affordable.

NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Pending
Introduced: 02/22/2017
Author: Lesser (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

**MA S 551**

**Introduced**  
**Passed 1st Committee**  
**Passed 1st Chamber**  
**Passed 2nd Committee**  
**Passed 2nd Chamber**  
**Enacted**

**DOCKET** 376  
**Title:** Improved Medication Management  
**Summary:** Reduces health care costs through improved medication management.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/22/2017
Author: L'Italian (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

**MA SD 1341**

**Introduced**  
**Passed 1st Committee**  
**Passed 1st Chamber**  
**Passed 2nd Committee**  
**Passed 2nd Chamber**  
**Enacted**
DOCKET 516
Title: Prescription Drug Coverage Out of Pocket Expenses
Summary: Concerns out of pocket expenses for prescription drug coverage.
Disposition: Pending
Author: DiDomenico (D)
Status: 02/24/2017 Assigned Senate Bill No. 516

Maryland

55. MD H 740

Introduced               Passed 1st Committee   Passed 1st Chamber   Passed 2nd Committee   Passed 2nd Chamber   Enacted

Title: Cancer Treatment Access Act
Summary: Prohibits a specified insurer, nonprofit health service plan, or health maintenance organization from imposing a step therapy or fail-first protocol on an insured or an enrollee for a specified prescription drug used in the treatment of a specified cancer under specified circumstances.
Disposition: Enacted
Introduced: 02/02/2017
Author: Angel (D)
Status: 05/25/2017 Signed by GOVERNOR.
05/25/2017 Chapter No. 678

56. MD H 1128

Introduced               Passed 1st Committee   Passed 1st Chamber   Passed 2nd Committee   Passed 2nd Chamber   Enacted

Title: Prescription Drugs
Summary: Prohibits insurers, nonprofit health service plans, and health maintenance organizations from making specified formulary changes during a plan year and the open enrollment period that precedes the plan year; applies the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after the specified date.
Disposition: Failed
Introduced: 02/09/2017
Author: Kelly A (D)
57. **MD H 1273**

**Title:** Pharmacists Substitution

**Summary:** Authorizes a pharmacist to substitute an interchangeable biological product for a prescribed product under specified circumstances; requires a pharmacist or the pharmacist's designee, except under specified circumstances, to inform specified consumers of the availability of an interchangeable biological product and the approximate cost difference as compared to a specified drug; requires the State Board of Pharmacy to maintain on its Web site a link to specified lists of biological products.

**NORD:** NORD supports this legislation.

**Disposition:** Enacted

**Introduced:** 02/10/2017

**Author:** Cullison (D)

**Status:** 05/25/2017 Signed by GOVERNOR.
05/25/2017 Chapter No. 726

58. **MD S 768**

**Title:** Health Insurance

**Summary:** Prohibits insurers, nonprofit health service plans, and health maintenance organizations from making specified formulary changes during the plan year and the open enrollment period that precedes the plan year; applies the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after October 1, 2017.

**Disposition:** Failed

**Introduced:** 02/03/2017

**Author:** Feldman (D)

**Status:** 03/13/2017 From SENATE Committee on FINANCE: Reported unfavorably. (11-0)
03/13/2017 Withdrawn from further consideration.

59. **MD S 997**

**Title:** Health Insurance

**Summary:** Prohibits insurers, nonprofit health service plans, and health maintenance organizations from making specified formulary changes during the plan year and the open enrollment period that precedes the plan year; applies the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after October 1, 2017.

**Disposition:** Failed

**Introduced:** 02/03/2017

**Author:** Feldman (D)

**Status:** 03/13/2017 From SENATE Committee on FINANCE: Reported unfavorably. (11-0)
03/13/2017 Withdrawn from further consideration.
<table>
<thead>
<tr>
<th>Title: Pharmacists Substitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary: Authorizes a pharmacist to substitute an interchangeable biological product for the prescribed product under specified circumstances; requires a pharmacist or the pharmacist's designee, except under specified circumstances, to inform specified consumers of the availability of an interchangeable biological product and the approximate cost difference as compared to a specified drug; requires the State Board of Pharmacy to maintain on its Web site a link to a specified list of biological products.</td>
</tr>
</tbody>
</table>

**NORD:** NORD supports this legislation. Actions: Submitted written testimony.

**Disposition:** Vetoed

**Introduced:** 02/03/2017

**Author:** Conway J (D)

**Status:** 05/26/2017 Vetoed by GOVERNOR - Duplicative.

---

### Maine

**60. ME H 198**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

**LD 265**

<table>
<thead>
<tr>
<th>Title: Lysosomal Storage Disorders Newborn Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary: Requires the Department of Health and Human Services to amend its rules in Chapter 283 relating to the newborn screening program by January 1, 2018 to add to the program the lysosomal storage disorders known as Krabbe, Pompe, Gaucher, Fabry and Niemann-Pick diseases. It directs the department to explore options to enter into contracts with other states to test samples collected for lysosomal storage disorders.</td>
</tr>
</tbody>
</table>

**NORD:** NORD supports this legislation

**Disposition:** Failed

**Introduced:** 01/27/2017

**Author:** Johansen (R)

**Status:** 05/11/2017 SENATE accepts Committee Report. 05/11/2017 SENATE adopts Majority Committee Report: Ought not to pass. 05/11/2017 In SENATE. Placed in Legislative File (DEAD).

---

**61. ME LR 1195**

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

---
Michigan

62. **MI HR 28**

- **Title:** Rare Disease Day Resolution
- **Summary:** Declares February 28, 2017, as Rare Disease Day in the state of Michigan.
- **Disposition:** Adopted
- **Introduced:** 02/28/2017
- **Sponsor:** Faris (D)
- **Status:** 02/28/2017 INTRODUCED. 02/28/2017 In HOUSE. Passed HOUSE.

Minnesota

63. **MN H 712**

- **Title:** Standards of Biological Products Substitution
- **Summary:** Relates to health; modifies and adds definitions; establishes standards for the substitution of biological products.
- **NORD:** NORD supports this legislation
- **Disposition:** Enacted
- **Introduced:** 02/01/2017
- **Author:** Albright (R)
- **Status:** 05/23/2017 Signed by GOVERNOR. 05/23/2017 Filed with Secretary of State. Chapter No. 84
**Title:** Biological Product Substitutions  
**Summary:** Relates to health; modifies and adds definitions; establishes standards for the substitution of biological products.  
**Disposition:** Failed  
**Introduced:** 02/20/2017  
**Author:** Nelson C (R)  
**Status:** 05/09/2017 Indefinitely postponed. See H. B. 712.

**Missouri**

65. **MO H 66**

**Title:** Newborn Screening Requirements  
**Summary:** Expands the newborn screening requirements to include spinal muscular atrophy (SMA) and Hunter syndrome.  
**NORD:** NORD supports this legislation  
**Disposition:** Failed - Adjourned  
**Introduced:** 01/04/2017  
**Sponsor:** Ruth (R)  
**Status:** 04/10/2017 Placed on Informal Calendar.

**Montana**

66. **MT H 233**

**Title:** Drug Product Selection Act  
**Summary:** Revises drug product selection laws to include biological products; provides definitions; requires reporting of drug product selection.  
**NORD:** NORD supports this legislation. Actions: Submitted written testimony.  
**Disposition:** Enacted
North Carolina

67. **NC H 270**

**Introduced:** 01/12/2017  
**Author:** Ehli (R)  
**Status:** 02/22/2017 Chaptered. Chapter No. 42

**Title:** Newborn Screening  
**Summary:** Directs the commission for public health to adopt rules to add a screening test for Pompe disease, Mucopolysaccharidosis Type I, and X-linked Adrenoleukodystrophy to the newborn screening program; increases the fee for newborn screening tests; appropriates funds to the Department of Health and Human Services, division of public health, to purchase necessary equipment and upgrades at the state laboratory of public health for newborn screening and all other laboratory operations.

**NORD:** NORD supports this legislation  
**Disposition:** Pending

---

68. **NC S 190**

**Introduced:** 03/07/2017  
**Author:** Davis D (D)  
**Status:** 03/07/2017 INTRODUCED.  
03/07/2017 To SENATE Committee on RULES AND OPERATIONS OF THE SENATE.

**Title:** Newborn Screening  
**Summary:** Directs the commission for public health to adopt rules to add a screening test for Pompe disease, Mucopolysaccharidosis Type I, and X-linked Adrenoleukodystrophy to the newborn screening program; increases the fee for newborn screening tests; appropriates funds to the Department of Health and Human Services, division of public health, to purchase necessary equipment and upgrades at the state laboratory of public health for newborn screening and all other laboratory operations.

**Disposition:** Pending

---

**Introduced:** 03/08/2017  
**Author:** Lambeth (R)  
**Status:** 03/08/2017 INTRODUCED.  
03/08/2017 To HOUSE Committee on HEALTH.
North Dakota

69. **ND H 1187**

**Title:** Medical Food Program for Phenylketonuria

**Summary:** Relates to the medical food program for phenylketonuria or maple syrup urine disease; relates to treatment for a positive diagnosis; provides for a registry of cases of metabolic diseases; provides for medical food for persons under a specified age regardless of income; relates to low-protein modified food products; provides for reimbursement from any government program that provides coverage to that individual for the treatment services provided by the department.

**NORD:** NORD supports this legislation

**Disposition:** Enacted

**Introduced:** 01/09/2017

**Author:** Delmore (D)

**Status:** 03/21/2017 Signed by GOVERNOR.

---

Nebraska

70. **NE L 481**

**Title:** Interchangeable Biological Products Drug Selections

**Summary:** Relates to the Pharmacy Practice Act; provides, changes and transfers definitions; restates intent and changes provisions relating to drug product selection; provides for drug product selection for interchangeable biological products.

**NORD:** NORD supports this legislation. Actions: Submitted written testimony.

**Disposition:** Enacted

**Introduced:** 01/17/2017

**Author:** Kuehn (NP)

**Status:** 05/09/2017 Signed by GOVERNOR.

---

New Hampshire

71. **NH H 443**

**Title:** Medical Food Program for Phenylketonuria

**Summary:** Relates to the medical food program for phenylketonuria or maple syrup urine disease; relates to treatment for a positive diagnosis; provides for a registry of cases of metabolic diseases; provides for medical food for persons under a specified age regardless of income; relates to low-protein modified food products; provides for reimbursement from any government program that provides coverage to that individual for the treatment services provided by the department.

**NORD:** NORD supports this legislation

**Disposition:** Enacted

**Introduced:** 01/09/2017

**Author:** Delmore (D)

**Status:** 03/21/2017 Signed by GOVERNOR.
**Title:** Prescription Drug Manufacturers

**Summary:** Prohibits prescription drug manufacturers from offering to pay or reimburse an individual for his or her insurance copayment.

**Disposition:** Failed

**Introduced:** 01/05/2017

**Author:** Kurk (R)

**Status:** 03/08/2017 Failed to pass HOUSE.

---

**New Jersey**

72. **NJ A 817**

**Introduced**

<table>
<thead>
<tr>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Title:** Disorders in Newborn Screening Program

**Summary:** Expands number of disorders included in newborn screening program.

**NORD:** NORD supports this legislation

**Disposition:** Pending

**Introduced:** 01/27/2016

**Sponsor:** Jimenez (D)

**Status:** 01/27/2016 INTRODUCED.

01/27/2016 To ASSEMBLY Committee on WOMEN AND CHILDREN.

---

73. **NJ A 902**

**Introduced**

<table>
<thead>
<tr>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Title:** Newborn Screening Specimen Disposal

**Summary:** Requires Department of Human Services (DHS) to dispose of newborn screening specimens within 60 days after testing.

**Disposition:** Pending

**Introduced:** 01/27/2016

**Sponsor:** Vainieri Huttle (D)

**Status:** 01/27/2016 INTRODUCED.

01/27/2016 To ASSEMBLY Committee on WOMEN AND CHILDREN.
Title: Patient Cost Sharing
Summary: Requires health insurers to limit patient cost-sharing and provide appeal process concerning certain prescription drug coverage.
NORD: NORD supports this legislation and provided in-person testimony and constituent visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/04/2016
Sponsor: Benson (D)
Status: 10/06/2016 From ASSEMBLY Committee on FINANCIAL INSTITUTIONS AND INSURANCE. (10-0)

Title: Rare Disease Advisory Council
Summary: Establishes the New Jersey Rare Disease Advisory Council.
Disposition: Pending
Introduced: 02/22/2016
Sponsor: Dancer (R)
Status: 02/22/2016 INTRODUCED.
02/22/2016 To ASSEMBLY Committee on HEALTH AND SENIOR SERVICES.

Title: Health Insurers to Limit Patient Cost Sharing
Summary: Requires health insurers to limit patient cost-sharing and provide appeal process concerning certain prescription drug coverage.
Disposition: Pending
Introduced: 01/12/2016
77. **NJ S 1283**

**Title:** Newborn Screening Program

**Summary:** Revises Newborn Screening program in Department of Health.

**Disposition:** Pending

**Introduced:** 02/08/2016

**Sponsor:** Vitale (D)

**Status:** 02/08/2016 INTRODUCED. 02/08/2016 To SENATE Committee on HEALTH, HUMAN SERVICES AND SENIOR CITIZENS.

78. **NJ S 1929**

**Title:** Insurance Coverage for Elemental Formula

**Summary:** Requires health insurance coverage for amino acid-based elemental formula.

**Disposition:** Pending

**Introduced:** 03/10/2016

**Sponsor:** Lesniak (D)

**Status:** 03/10/2016 INTRODUCED. 03/10/2016 To SENATE Committee on COMMERCE.

79. **NJ SJR 33**

**Title:** Rare Disease Awareness Day

**Summary:** Designates last day of February of each year as Rare Disease Awareness Day in New Jersey.

**Disposition:** Pending

**Introduced:** 02/11/2016
80. **NM H 244**

**Title:** Prescription Drug Coverage Step Therapy

**Summary:** Relates to health coverage; enacts new sections of the health care purchasing act, the public assistance act, the New Mexico insurance code, the health maintenance organization law and the nonprofit health care plan law to establish guidelines relating to step therapy for prescription drug coverage.

**NORD:** NORD supports this legislation. Actions: Submitted written testimony.

**Disposition:** Failed - Adjourned

**Introduced:** 01/25/2017

**Author:** Thomson (D)

**Status:** 03/11/2017 From SENATE Committee on CORPORATIONS AND TRANSPORTATION: Do pass as amended.

81. **NM H 260**

**Title:** Regulation of Biosimilar Products

**Summary:** Relates to health; amends the New Mexico Drug, Device and Cosmetic Act to provide for regulation of biosimilar products.

**Disposition:** Enacted

**Introduced:** 01/26/2017

**Author:** Armstrong (D)

**Status:** 04/06/2017 Signed by GOVERNOR.

04/06/2017 Chaptered. Chapter No. 48
Title: Prescription Drug Coverage Step Therapy
Summary: Relates to health coverage; enacts new sections of the health care purchasing act, the public assistance act, the New Mexico insurance code, the health maintenance organization law and the nonprofit health care plan law to establish guidelines relating to step therapy for prescription drug coverage.

Disposition: Failed - Adjourned
Introduced: 01/25/2017
Author: Stefanics (D)
Status: 03/01/2017 From SENATE Committee on CORPORATIONS AND TRANSPORTATION: Do pass as amended.
03/01/2017 Re-referred to SENATE Committee on FINANCE.

83. **NM S 180**

Introduced  Passed  Passed  Passed  Passed  Enacted
1st Committee  1st Chamber  2nd Committee  2nd Chamber

Title: Regulation of Biosimilar Products
Summary: Relates to health; amends the New Mexico drug, device and cosmetic act to provide for regulation of biosimilar products.

Disposition: Failed - Adjourned
Introduced: 01/25/2017
Author: Ortiz y Pino (D)
Status: 03/11/2017 From HOUSE Committee on BUSINESS AND INDUSTRY: Do pass.

84. **NM SM 108**

Introduced  Passed  Passed  Adopted
1st Committee  1st Chamber

Title: World Rare Disease Day
Summary: Declares February 28, 2017 World Rare Disease Day in the Senate.

Disposition: Adopted
Introduced: 02/27/2017
Author: Rodriguez (D)
Status: 02/28/2017 In SENATE. Withdrawn from table.
02/28/2017 Passed SENATE. (42-0)
85. NV A 245

Title: Dispensing of Biological Products
Summary: Relates to pharmacy; requires a pharmacist or his or her designee to make certain entries any time a biological product is dispensed under certain circumstances; requires the dispensing of an interchangeable biological product in substitution for a prescribed biological product under certain circumstances; requires the State Board of Pharmacy to maintain certain lists of approved interchangeable biological products, published by the United States Food and Drug Administration, on its Internet website.

Disposition: Enacted
Introduced: 02/27/2017
Author: Benitez-Thompson (D)
Status: 05/26/2017 Signed by GOVERNOR.
05/26/2017 Chaptered. Chapter No. 143

86. NV S 265

Title: Prescription Drugs
Summary: Relates to prescription drugs; requires the Department of Health and Human Services to compile a list of prescription drugs essential for treating diabetes; requires the manufacturer of a prescription drug included on the list to report certain information; requires a manufacturer to notify the Department in advance of planned price increases; provides for requirements concerning pharmaceutical sales representatives, contributions to certain nonprofit organizations, private schools, and insurer notices.

NORD: NORD opposes this legislation because it put onerous requirements on non-profits and applies provisions that could impact rare disease research.

Disposition: Vetoed
Introduced: 03/14/2017
Author: Cancela (D)
Status: 06/02/2017 Vetoed by GOVERNOR.

New York

87. NY A 1076

Introduced 1st Committee 1st Chamber 2nd Committee 2nd Chamber Enacted

Title:
Summary:
Title: DNA Testing for Newborns

Summary: Requires hospitals to provide parents of newborns with the option to have a DNA test performed on their child or have a blood sample taken from the child and preserved for future DNA testing.

Disposition: Pending

Introduced: 01/10/2017

Sponsor: Pretlow (D)

Status: 01/10/2017 INTRODUCED.
01/10/2017 To ASSEMBLY Committee on HEALTH.

---

Title: Interchangeable Biological Products

Summary: Relates to interchangeable biological products; enacts provisions relating to substitutions of biological products by pharmacists.

NORD: NORD supports this legislation.

Disposition: Pending

Introduced: 03/01/2017

Sponsor: Hannon (R)

Status: 06/21/2017 Withdrawn from SENATE Committee on HIGHER EDUCATION.
06/21/2017 To SENATE Committee on RULES.
06/21/2017 From SENATE Committee on RULES. (23-1)
06/21/2017 Substituted by A7509A

---

Ohio

Title: Step Therapy Protocol Requirements

Summary: Adopts requirements related to step therapy protocols implemented by health plan issuers and the Department of Medicaid.

Disposition: Pending

Introduced: 02/21/2017
OH S 56

Title: Step Therapy Protocols
Summary: Adopts requirements related to step therapy protocols implemented by health plan issuers and the Department of Medicaid.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/14/2017
Sponsor: Lehner (R)
Status: 02/15/2017 From SENATE Committee on RULES AND REFERENCE: Recommended referral. 02/15/2017 In SENATE. To second reading. Read a second time. 02/15/2017 To SENATE Committee on HEALTH, HUMAN SERVICES, AND MEDICAID.

OR D 1255

Title: Health Authority
Summary: Directs Oregon Health Authority to establish and operate statewide database for collection and dissemination of orders for rare disease emergency response medical treatment for the purpose of ensuring safe treatment of individuals with rare diseases in emergency situations; creates Oregon ORDER Database Advisory Committee to advise authority on establishment, operation and evaluation of database.

NORD: NORD supports this legislation. Actions: provided in-person testimony and legislative visits as part of Rare Disease Day
Disposition: Pending
Author: Senate Committee on Education and General Government
Status: 02/01/2017 Assigned SENATE Bill No. 215
Title: Prescription Drug Formulary for Insurance Code
Summary: Defines prescription drug formulary for purposes of Insurance Code; requires carrier offering health benefit plan to small employers, groups or individuals to make specified information about prescription drug formularies available on carrier's website and through toll-free telephone number; prohibits carrier from making changes to prescription drug formulary more than once every specified period unless based on alert issued by United States Food and Drug Administration.

Disposition: Pending
Author: Senate Committee on Health Care
Status: 12/12/2016 FILED.

93. OR S 237

Title: Group Health Benefit Plans
Summary: Requires at least 25 percent of carrier's individual and group health benefit plans within each metal level of coverage to have copayment-only cost sharing requirements.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/01/2017
Author: Joint Interim Human Services and Early Childhood Development
Status: 03/21/2017 Public Hearing held.

94. OR S 526

Title: Step Therapy Protocol Imposed by Insurer
Summary: Modifies requirements applicable to step therapy protocol imposed by insurer; allows patient to appeal insurer's denial of step therapy override.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
95. OR S 808

**Title:** Health Testing Service

**Summary:** Provides that with respect to newborn screening, Oregon Health Authority shall specify that person providing newborn screening may conduct tests for conditions listed on most recent edition of Recommended Uniform Screening Panel by United States Department of Health and Human Services; specifies that person providing newborn screening shall test for certain condition through implementation of laboratory developed test approved by federal Food and Drug Administration, under certain circumstances.


Disposition: Pending

Introduced: 02/16/2017
Author: Boquist (R)
Status: 04/24/2017 From SENATE Committee on HEALTH CARE: Do pass with amendment. 04/24/2017 Printed A Engrossed Text. 04/24/2017 To JOINT Committee on WAYS AND MEANS.

Pennsylvania

96. PA H 239

**PN** 2005

**Title:** Rare Disease Advisory Council Act

**Summary:** Establishes the Rare Disease Advisory Council and providing for its powers and duties; provides for duties of the Department of Health, the Insurance Department, the Department of Human Services and the Department of Education.

NORD: NORD supports this legislation. Actions: Submitted written testimony. Planing in-person legislative visits during Rare Disease Day in May.

Disposition: Pending

Introduced: 02/01/2017
Author: Toepel (R)
Status: 06/28/2017 In SENATE. Read third time. Passed SENATE. *****To HOUSE for
Rhode Island

97. **PA HR 55**

Introduced 02/02/2017
Passed 1st Committee
Passed 1st Chamber

**PN 277**
Title: Rare Disease Day
Summary: Recognizes March 14, 2017, as "Rare Disease Day".
Disposition: Pending
Introduced: 02/02/2017
Author: Toepel (R)
Status: 03/20/2017 To HOUSE Committee on RULES.

98. **PA SR 29**

Introduced 02/08/2017
Passed 1st Committee
Passed 1st Chamber
Adopted

**PN 308**
Title: Rare Disease Day
Summary: Recognizes February 28, 2017, as Rare Disease Day.
Disposition: Adopted
Introduced: 02/08/2017
Author: Costa J (D)
Status: 02/08/2017 FILED.
02/08/2017 INTRODUCED.
02/08/2017 Passed SENATE.

Rhode Island

99. **RI H 5636**

Introduced 02/08/2017
Passed 1st Committee
Passed 1st Chamber
Passed 2nd Committee
Passed 2nd Chamber
Enacted

**Title:** Insurance Step Therapy Protocols
**Summary:** Would require health insurers, nonprofit hospital service corporations, nonprofit medical
service corporations and health maintenance organizations that issue policies that provide
coverage for prescription drugs and use step therapy protocols, to base step therapy
protocols on appropriate clinical practice guidelines or published peer review data developed
by independent experts with knowledge of the condition or conditions under consideration;
that patients be exempt from step therapy protocols/.

NORD:  NORD supports this legislation. Actions: Submitted written testimony.

Disposition:  Pending

Introduced:  03/01/2017

Author:  Blazejewski (D)

Status:  04/04/2017 In HOUSE Committee on CORPORATIONS: Committee recommends measure to
be held for further study.

100.  SC H 3323

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

Title:  Payment of Insurance Premiums

Summary:  Allows the payment of insurance premiums and other cost sharing by third parties on behalf
of individuals insured by qualified health plans.

NORD:  NORD supports. Actions: Submitted written testimony and constituent messages. Conducted
in-person legislative visits during Rare Disease Day.

Disposition:  Pending - Carryover

Introduced:  01/10/2017

Author:  Stringer (R)

Status:  01/10/2017 INTRODUCED.
101.  SC H 3438

<table>
<thead>
<tr>
<th>Introduced</th>
<th>Passed 1st Committee</th>
<th>Passed 1st Chamber</th>
<th>Passed 2nd Committee</th>
<th>Passed 2nd Chamber</th>
<th>Enacted</th>
</tr>
</thead>
</table>

Title:  Drug Product Selection Act

Summary:  Relates to definitions in the Drug Product Selection Act; includes interchangeable biological
products in the definition of substitute; relates to the substitution of equivalent drugs; allows
pharmacists to substitute interchangeable biological products when appropriate; relates to
label requirements for prescriptions so as to include interchangeable biological products;
requires pharmacies to keep records of dispensed biological products; requires a database for
all approved biological products.

NORD:  NORD supports this legislation. Actions: Submitted written testimony.
102. **SC S 299**

**Introduced:** 01/12/2017  
**Author:** Henderson (R)  
**Status:** 04/28/2017 Act No. 11

**Title:** Drug Product Selection Act  
**Summary:** Relates to definitions in the Drug Product Selection Act; includes interchangeable biological products; relates to the substitution of equivalent drugs; allows a pharmacist to substitute an interchangeable biological product for a specific biological product; relates to the substitution of prescriptions by pharmacists; allows pharmacists to substitute interchangeable biological products when appropriate; relates to definitions in the pharmacy practice act; adds definitions for biological product.

**Disposition:** Pending - Carryover  
**Introduced:** 01/24/2017  
**Author:** Bryant (R)  
**Status:** 01/24/2017 INTRODUCED.  
01/24/2017 To SENATE Committee on MEDICAL AFFAIRS.

103. **TN S 1138**

**Introduced:** 01/24/2017  
**Author:** Henderson (R)  
**Status:** 04/28/2017 Act No. 11

**Title:** Pediatric Rare Disease Treatment Information Act  
**Summary:** Relates to Children; enacts the Access to Pediatric Rare Disease Treatment Information Act; provides for sharing of essential treatment information for children with cancer among certain health care institutions.

**Disposition:** Pending - Carryover  
**Introduced:** 02/09/2017  
**Author:** Kyle (D)  
**Status:** 02/13/2017 To SENATE Committee on HEALTH AND WELFARE.
Title: Newborn Screening Tests for Adrenoleukodystrophy
Summary: Relates to newborn screening tests for adrenoleukodystrophy.
NORD: NORD supports this legislation.
Disposition: Failed - Adjourned
Introduced: 01/17/2017
Author: Meyer (R)
Status: 03/07/2017 Considered in public hearing.
03/07/2017 Testimony taken in committee.
03/07/2017 Left pending in committee.

Title: Step Therapy Protocols for Health Benefit Plans
Summary: Relates to step therapy protocols required by a health benefit plan in connection with prescription drug coverage.
Disposition: Failed - Adjourned
Introduced: 02/01/2017
Author: Bonnen G (R)
Status: 05/08/2017 In HOUSE Tabled.

Title: Contract Requirements for Prescription Drug Benefits
Summary: Relates to contract requirements for prescription drug benefits provided by Medicaid managed care organizations.
NORD: NORD supports and provided written testimony
Disposition: Enacted
Introduced: 02/15/2017

Texas

107. **TX H 1937**

- **Title:** Newborn Screening Tests for Adrenoleukodystrophy
- **Summary:** Relates to newborn screening tests for adrenoleukodystrophy.
- **Disposition:** Failed - Adjourned
- **Introduced:** 02/15/2017
- **Author:** Villalba (R)
- **Status:** 03/13/2017 To HOUSE Committee on PUBLIC HEALTH.

108. **TX S 680**

- **Title:** Health Benefit Plan Step Therapy Protocols
- **Summary:** Relates to step therapy protocols required by a health benefit plan in connection with prescription drug coverage; provides a health benefit plan issuer that requires a step therapy protocol before providing coverage for a prescription drug must establish, implement, and administer the step therapy protocol in accordance with clinical review criteria readily available to the health care industry; provides the health benefit plan issuer shall take into account the needs of atypical patient populations.
- **NORD:** NORD supports. Actions: Submitted written testimony and constituent messages. Conducted in-person legislative visits during and constituent outreach during Rare Disease Day.
- **Disposition:** Enacted
- **Introduced:** 01/31/2017
- **Author:** Hancock (R)
- **Status:** 06/13/2017 Filed with Secretary of State. Chapter No. 103

Utah

109. **UT H 266**

- **Title:** Newborn Screening Tests for Adrenoleukodystrophy
- **Summary:** Relates to newborn screening tests for adrenoleukodystrophy.
- **Disposition:** Failed - Adjourned
- **Introduced:** 02/15/2017
- **Author:** Raymond (D)
- **Status:** 06/15/2017 Signed by GOVERNOR.
Title: Health Insurance Provisions
Summary: Amends health insurance provisions in the Insurance Code; prohibits the use of step therapy for pharmaceuticals unless certain conditions are met; requires a health insurer to authorize bypass of a step drug when certain conditions are met; addresses adverse benefit determinations.

NORD: NORD supports this legislation.
Disposition: Failed
Introduced: 02/01/2017
Author: Hutchings (R)
Status: 03/09/2017 Enacting clause struck.

Virginia

110. VA H 362

Title: Step Therapy Protocols
Summary: Relates to step therapy protocols; relates to disclosures; requires health insurers that limit coverage for prescription drugs through the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient.

Disposition: Failed - Adjourned
Introduced: 01/13/2016
Author: Davis (R)
Status: 02/02/2016 In HOUSE Committee on COMMERCE AND LABOR: Continued to 2017.

111. VA H 601

Title: Health Insurance
Summary: Relates to health insurance; relates to mandated coverage for treatment of inborn errors of metabolism; requires health carriers to provide coverage for treatment of inborn errors of metabolism that involve amino acid, carbohydrate, and fat metabolism and for which medically standard methods of diagnosis, treatment, and monitoring exist.

Disposition: Failed - Adjourned
Introduced: 01/13/2016
Author: Murphy (D)
Status: 01/26/2016 In HOUSE Committee on COMMERCE AND LABOR: Continued to 2017.
Step Therapy Protocols

Title: Relates to step therapy protocols; relates to disclosures; requires health insurers that limit coverage for prescription drugs through the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient; provides that a step therapy protocol is a protocol or program that establishes the specific sequence in which prescription drugs for a specified medical condition are medically appropriate for a particular patient.

Summary: Requires health insurers that limit coverage for prescription drugs through the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient; provides that a step therapy protocol is a protocol or program that establishes the specific sequence in which prescription drugs for a specified medical condition are medically appropriate for a particular patient.

Disposition: Failed
Introduced: 01/11/2017
Author: Davis (R)
Status: 02/08/2017 In HOUSE Committee on COMMERCE AND LABOR: Left in committee.

Step Therapy

Title: Relates to step therapy; relates to psychiatric medicines; prohibits a health insurer or other carrier from using step therapy in a manner that results in a denial of or delay in coverage for any psychiatric medication under a health insurance policy or plan; applies only to health insurance policies or plans that provide coverage for prescription drugs on an outpatient basis; provides that if the health benefit plan utilizes a closed drug formulary, the prohibition applies only to psychiatric medications.

Summary: Relates to step therapy; relates to psychiatric medicines; prohibits a health insurer or other carrier from using step therapy in a manner that results in a denial of or delay in coverage for any psychiatric medication under a health insurance policy or plan; applies only to health insurance policies or plans that provide coverage for prescription drugs on an outpatient basis; provides that if the health benefit plan utilizes a closed drug formulary, the prohibition applies only to psychiatric medications.

Disposition: Failed
Introduced: 01/13/2016
Author: DeSteph (R)
Status: 02/01/2016 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (15-0)
**Title:** Step Therapy Protocols  
**Summary:** Relates to step therapy protocols; requires health benefit plans that restrict the use of any prescription drug through the use of a step therapy protocol to have in place a clear, convenient, and expeditious process for a prescribing medical provider to request an override of such restrictions for a patient; requires website posting.

**Disposition:** Failed  
**Introduced:** 01/13/2016  
**Author:** DeSteph (R)  
**Status:** 02/01/2016 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (15-0)

---

**Title:** Step Therapy Protocols  
**Summary:** Relates to step therapy protocols; requires health benefit plans that restrict the use of any prescription drug through the use of a step therapy protocol to have in place a clear, convenient, and expeditious process for a prescribing medical provider to request an override of such restrictions for a patient.

**Disposition:** Failed  
**Introduced:** 01/11/2017  
**Author:** DeSteph (R)  
**Status:** 01/23/2017 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (9-6)

---

**Title:** Health Coverage for Enteral Formula for Home Use  
**Summary:** Relates to health insurance coverage for enteral formula for home use.  
**NORD:** NORD supports this legislation.

**Disposition:** Pending  
**Introduced:** 01/17/2017  
**Author:** Weed (D)  
**Status:** 01/18/2017 To HOUSE Committee on HEALTH CARE.
117. **VT H 447**

**Title:** Interchangeable Biological Products  
**Summary:** Relates to interchangeable biological products.  
**NORD:** NORD supports this legislation. Actions: Submitted written testimony.  
**Disposition:** Pending  
**Introduced:** 02/22/2017  
**Author:** Copeland-Hanzas (D)  
**Status:** 02/23/2017 To HOUSE Committee on HEALTH CARE.

118. **VT S 19**

**Title:** Out of Pocket Limit for Prescription Drugs  
**Summary:** Relates to preserving the out-of-pocket limit for prescription drugs in bronze-level Exchange plans.  
**NORD:** NORD supports this legislation.  
**Disposition:** Pending  
**Introduced:** 01/11/2017  
**Author:** Ayer (D)  
**Status:** 02/14/2017 SENATE Committee on HEALTH AND WELFARE relieved of further consideration.  
02/14/2017 To SENATE Committee on FINANCE.

119. **VT S 92**

**Title:** Interchangeable Biological Products  
**Summary:** Relates to interchangeable biological products.  
**NORD:** NORD supports this legislation. Actions: Submitted written testimony.  
**Disposition:** Pending
**Washington**

120. **WA S 5626**

- **Introduced:** 02/21/2017
- **Author:** Lyons (D)
- **Status:** 03/28/2017 To HOUSE Committee on HEALTH CARE.

**Title:** Metastatic Cancer

**Summary:** Prohibits the use of step therapy in treatments for stage four advanced, metastatic cancer.

**Disposition:** Pending - Carryover

- **Introduced:** 02/01/2017
- **Author:** Miloscia (R)
- **Status:** 06/21/2017 2017 3rd SPECIAL SESSION: By Order of Resolution - Reintroduced and retained in present status.

121. **WA S 5757**

- **Introduced:** 02/08/2017
- **Author:** Rivers (R)
- **Status:** 06/21/2017 2017 3rd SPECIAL SESSION: By Order of Resolution - Reintroduced and retained in present status.

**West Virginia**

122. **WV H 2300**

- **Introduced:** 02/01/2017
- **Author:**
- **Status:**
**Title:** Step Therapy Protocols

**Summary:** Regulates step therapy protocols in health benefit plans which provide prescription drug benefits; provides that upon the granting of a step therapy override determination, the health plan issuer or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient’s treating healthcare provider, provided such prescription drug is a covered prescription drug under such policy or contract.

**NORD:** NORD supports this legislation. Actions: Submitted written testimony.

**Disposition:** Enacted

**Introduced:** 02/09/2017

**Sponsor:** Kelly (R)

**Status:** 05/23/2017 Act No. 131

---

**Title:** Drug Benefits Prior Authorization Provisions

**Summary:** Requires provisions for prior authorization of drug benefits by insurers.

**Disposition:** Failed - Adjourned

**Introduced:** 02/08/2017

**Sponsor:** Ferns (R)

**Status:** 02/08/2017 INTRODUCED. 02/08/2017 To SENATE Committee on BANKING AND INSURANCE.

---

**Title:** Insurance Coverage for Inherited Enzymatic Disorders

**Summary:** Relates to mandatory insurance coverage, up to the age of twenty, for certain medical foods for amino acid-based formulas; provides a list of diagnosed conditions for which insurance coverage should extend; provides that coverage extends to medically necessary foods for home use when prescribed by a physician; defines terms; provides for exclusions.

**NORD:** NORD supports this legislation. Actions: Submitted written testimony and conducted constituent outreach to legislators.

**Disposition:** Failed - Adjourned

**Introduced:** 03/07/2017

**Sponsor:** Takubo (R)

**Status:** 03/31/2017 To HOUSE Committee on JUDICIARY.
For more information, please contact
Tim Boyd at tboyd@rarediseases.org